Role of post transplant maintenance therapy in multiple myeloma: Results from a developing country

Sengar, Manju; Kumar, Lakshya; Ganessan, K; Khattry, Navin; Mohanty, Smruti R.; Kochupillai, V.

doi:10.1200/jco.2005.23.16_suppl.6731

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the initial period of this study, we used IFN-a as post transplant maintenance therapy. We switched over to low-dose thalidomide (50 mg daily) from January 2002 onwards based on our initial observations 37 and those by the French Group. 38 Maintenance therapy was generally tolerated well, requiring discontinuation in three patients owing to toxicity.…”

Section: Discussionmentioning

confidence: 99%

High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country

Kumar

Ghosh

Ganessan

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

We analyzed the results of 108 patients (78 males and 30 females) with multiple myeloma who underwent autologous stem cell transplantation (ASCT). The median age of patients was 52 years (range, 26-68 years). High-dose melphalan (200 mg/m 2 ) was used for conditioning. In all, 66 (61%) patients had evidence of chemo-sensitive disease before transplant. After ASCT 79.6% of patients responded: complete response 36%, very good partial response 29.6%, and partial response 13.9%. Complete response rate was higher for patients with chemo-sensitive disease; 33 of 66 (50.0%) patients achieved complete response compared with 7 of 42 (14.3%) patients with progressive disease, Po0.01. Response rates to ASCT were significantly low for patients with Hb p8.5 g/dl, serum albumin p3.3 g/dl, b-2 microglobulin 45.5 mg/l, International Staging System stage III at diagnosis and 412 months interval from diagnosis to transplant. Grade III-IV mucositis was the major regimen-related toxicity. At a median follow-up of 70 months, the median overall survival and event free survival (EFS) were 71 and 42 months, respectively. Estimated overall survival and EFS at 60 months were 54.4 ± 0.05% (s.e.) and 49.3 ± 0.05% (s.e.), respectively. Survival was significantly better for patients with pre-transplant chemosensitive disease and for those who achieved complete response following transplant.

show abstract

Section: Discussionmentioning

confidence: 99%